The Impact of a Breast Cancer Risk Assessment on the Decision for Gender-Affirming Chest Masculinization Surgery in Transgender and Gender-Diverse Individuals: A Pilot Single-Arm Educational Intervention Trial.
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
28 Jun 2024
28 Jun 2024
Historique:
received:
27
03
2024
accepted:
21
05
2024
medline:
28
6
2024
pubmed:
28
6
2024
entrez:
28
6
2024
Statut:
aheadofprint
Résumé
Persons assigned female or intersex at birth and identify as transgender and/or gender-diverse (TGD) may undergo gender-affirming chest masculinization surgery (GACMS); however, GACMS is not considered equivalent to risk-reducing mastectomies (RRM). This study aimed to estimate the prevalence of elevated breast cancer (BC) risk in TGD persons, compare self-perceived versus calculated risk, and determine how risk impacts the decision for GACMS versus RRM. A prospective single-arm pilot educational intervention trial was conducted in individuals assigned female or intersex at birth, age ≥ 18 years, considering GACMS, without a BC history or a known pathogenic variant. BC risk was calculated using the Tyrer-Cuzik (all) and Gail models (age ≥ 35 years). Elevated risk was defined as ≥ 17%. Twenty-five (N = 25) participants were enrolled with a median age of 24.0 years (interquartile range, IQR 20.0-30.0 years). All were assigned female sex at birth, most (84%) were Non-Hispanic (NH)-White, 48% identified as transgender and 40% as nonbinary, and 52% had a first- and/or second-degree family member with BC. Thirteen (52%) had elevated risk (prevalence 95% confidence interval (CI) 31.3-72.2%). Median self-perceived risk was 12% versus 17.5% calculated risk (p = 0.60). Of the 13 with elevated risk, 5 (38.5%) underwent/are scheduled to undergo GACMS, 3 (23%) of whom underwent/are undergoing RRM. Over half of the cohort had elevated risk, and most of those who moved forward with surgery chose to undergo RRM. A BC risk assessment should be performed for TGD persons considering GACMS. Future work is needed to examine BC incidence and collect patient-reported outcomes. Trial Registration Number ClinicalTrials.gov (No. NCT06239766).
Sections du résumé
BACKGROUND
BACKGROUND
Persons assigned female or intersex at birth and identify as transgender and/or gender-diverse (TGD) may undergo gender-affirming chest masculinization surgery (GACMS); however, GACMS is not considered equivalent to risk-reducing mastectomies (RRM). This study aimed to estimate the prevalence of elevated breast cancer (BC) risk in TGD persons, compare self-perceived versus calculated risk, and determine how risk impacts the decision for GACMS versus RRM.
METHODS
METHODS
A prospective single-arm pilot educational intervention trial was conducted in individuals assigned female or intersex at birth, age ≥ 18 years, considering GACMS, without a BC history or a known pathogenic variant. BC risk was calculated using the Tyrer-Cuzik (all) and Gail models (age ≥ 35 years). Elevated risk was defined as ≥ 17%.
RESULTS
RESULTS
Twenty-five (N = 25) participants were enrolled with a median age of 24.0 years (interquartile range, IQR 20.0-30.0 years). All were assigned female sex at birth, most (84%) were Non-Hispanic (NH)-White, 48% identified as transgender and 40% as nonbinary, and 52% had a first- and/or second-degree family member with BC. Thirteen (52%) had elevated risk (prevalence 95% confidence interval (CI) 31.3-72.2%). Median self-perceived risk was 12% versus 17.5% calculated risk (p = 0.60). Of the 13 with elevated risk, 5 (38.5%) underwent/are scheduled to undergo GACMS, 3 (23%) of whom underwent/are undergoing RRM.
CONCLUSIONS
CONCLUSIONS
Over half of the cohort had elevated risk, and most of those who moved forward with surgery chose to undergo RRM. A BC risk assessment should be performed for TGD persons considering GACMS. Future work is needed to examine BC incidence and collect patient-reported outcomes. Trial Registration Number ClinicalTrials.gov (No. NCT06239766).
Identifiants
pubmed: 38940898
doi: 10.1245/s10434-024-15701-2
pii: 10.1245/s10434-024-15701-2
doi:
Banques de données
ClinicalTrials.gov
['NCT06239766']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Advancing a Healthier Wisconsin Endowment
ID : 9520699
Informations de copyright
© 2024. Society of Surgical Oncology.
Références
Key findings about LGBTQ+ Americans. Pew Research Center. Published June 23, 2023. https://www.pewresearch.org/short-reads/2023/06/23/5-key-findings-about-lgbtq-americans . Accessed January 30, 2024.
What percentage of the US population is transgender? USA Facts. Published August 3, 2023. https://usafacts.org/articles/what-percentage-of-the-us-population-is-transgender/#footnote-source-1 . Accessed February 1, 2024.
Meerwijk EL, Sevelius JM. Transgender population size in the United States: a meta-regression of population-based probability samples. Am J Public Health. 2017;107(2):e1–8. https://doi.org/10.2105/AJPH.2016.303578 .
doi: 10.2105/AJPH.2016.303578
pubmed: 28075632
pmcid: 5227946
Canner JK, Harfouch O, Kodadek LM, et al. Temporal trends in gender-affirming surgery among transgender patients in the United States. JAMA Surg. 2018;153(7):609–16. https://doi.org/10.1001/jamasurg.2017.6231 .
doi: 10.1001/jamasurg.2017.6231
pubmed: 29490365
pmcid: 5875299
Wright JD, Chen L, Suzuki Y, Matsuo K, Hershman DL. National estimates of gender-affirming surgery in the US. JAMA Netw Open. 2023;6(8):e2330348. https://doi.org/10.1001/jamanetworkopen.2023.30348 .
doi: 10.1001/jamanetworkopen.2023.30348
pubmed: 37610753
pmcid: 10448302
Akhavan AA, Sandhu S, Ndem I, Ogunleye AA. A review of gender affirmation surgery: What we know, and what we need to know. Surgery. 2021;170(1):336–40. https://doi.org/10.1016/j.surg.2021.02.013 .
doi: 10.1016/j.surg.2021.02.013
pubmed: 33741180
Clarke CN, Cortina CS, Fayanju OM, Dossett LA, Johnston FM, Wong SL. Breast cancer risk and screening in transgender persons: a call for inclusive care. Ann Surg Oncol. 2022;29(4):2176–80. https://doi.org/10.1245/s10434-021-10217-5 .
doi: 10.1245/s10434-021-10217-5
pubmed: 34097159
Jatoi I, Kemp Z. Risk-reducing mastectomy. JAMA. 2021;325(17):1781–2. https://doi.org/10.1001/jama.2020.22414 .
doi: 10.1001/jama.2020.22414
pubmed: 33944884
Jakub JW, Peled AW, Gray RJ, et al. Oncologic safety of prophylactic nipple-sparing mastectomy in a population with BRCA mutations: a multi-institutional study. JAMA Surg. 2018;153(2):123–9. https://doi.org/10.1001/jamasurg.2017.3422 .
doi: 10.1001/jamasurg.2017.3422
pubmed: 28903167
Garstka M, Henriquez A, Kelly BN, et al. How protective are nipple-sparing prophylactic mastectomies in BRCA1 and BRCA2 mutation carriers? Ann Surg Oncol. 2021;28(10):5657–62. https://doi.org/10.1245/s10434-021-10445-9 .
doi: 10.1245/s10434-021-10445-9
pubmed: 34296361
Stone JP, Hartley RL, Temple-Oberle C. Breast cancer in transgender patients: a systematic review. Part 2: female to male. Eur J Surg Oncol. 2018;44(10):1463–8. https://doi.org/10.1016/j.ejso.2018.06.021 .
doi: 10.1016/j.ejso.2018.06.021
pubmed: 30037639
Cortina CS, Kong AL. Chest mass in a transgender man after top surgery. Lancet Oncol. 2023;24(1):e57. https://doi.org/10.1016/S1470-2045(22)00545-9 .
doi: 10.1016/S1470-2045(22)00545-9
pubmed: 36603928
Fledderus AC, Gout HA, Ogilvie AC, van Loenen DKG. Breast malignancy in female-to-male transsexuals: systematic review, case report, and recommendations for screening. Breast. 2020;53:92–100. https://doi.org/10.1016/j.breast.2020.06.008 .
doi: 10.1016/j.breast.2020.06.008
pubmed: 32679529
pmcid: 7375644
Almazan AN, Keuroghlian AS. Association between gender-affirming surgeries and mental health outcomes. JAMA Surg. 2021;156(7):611–8. https://doi.org/10.1001/jamasurg.2021.0952 .
doi: 10.1001/jamasurg.2021.0952
pubmed: 33909023
pmcid: 8082431
Cortina CS. Assessing breast and ovarian cancer risk prior to gender-affirming surgery. JAMA Surg. 2023;158(4):339–40. https://doi.org/10.1001/jamasurg.2022.5447 .
doi: 10.1001/jamasurg.2022.5447
pubmed: 36630117
Safer JD. Research gaps in medical treatment of transgender/nonbinary people. J Clin Invest. 2021;131(4):e142029. https://doi.org/10.1172/JCI142029 .
doi: 10.1172/JCI142029
pubmed: 33586675
pmcid: 7880308
Cortina CS. Inclusion and reporting of transgender and nonbinary persons in clinical trials and tumor registries-the time is now. JAMA Oncol. 2022;8(8):1097–8. https://doi.org/10.1001/jamaoncol.2022.1638 .
doi: 10.1001/jamaoncol.2022.1638
pubmed: 35679027
Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12–49. https://doi.org/10.3322/caac.21820 .
doi: 10.3322/caac.21820
pubmed: 38230766
Rockhill B, Spiegelman D, Byrne C, Hunter DJ, Colditz GA. Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention. JNCI J Natl Cancer Inst. 2001;93(5):358–66. https://doi.org/10.1093/jnci/93.5.358 .
doi: 10.1093/jnci/93.5.358
pubmed: 11238697
Chay WY, Ong WS, Tan PH, et al. Validation of the Gail model for predicting individual breast cancer risk in a prospective nationwide study of 28,104 Singapore women. Breast Cancer Res. 2012;14(1):R19. https://doi.org/10.1186/bcr3104 .
doi: 10.1186/bcr3104
pubmed: 22289271
pmcid: 3496137
Nickson C, Procopio P, Velentzis LS, et al. Prospective validation of the NCI breast cancer risk assessment tool (Gail Model) on 40,000 Australian women. Breast Cancer Res. 2018;20(1):155. https://doi.org/10.1186/s13058-018-1084-x .
doi: 10.1186/s13058-018-1084-x
pubmed: 30572910
pmcid: 6302513
Gail MH, Mai PL. Comparing breast cancer risk assessment models. J Natl Cancer Inst. 2010;102(10):665–8. https://doi.org/10.1093/jnci/djq141 .
doi: 10.1093/jnci/djq141
pubmed: 20427429
Kurian AW, Hughes E, Simmons T, et al. Performance of the IBIS/Tyrer–Cuzick model of breast cancer risk by race and ethnicity in the Women’s Health Initiative. Cancer. 2021;127(20):3742–50. https://doi.org/10.1002/cncr.33767 .
doi: 10.1002/cncr.33767
pubmed: 34228814
Gallagher S, Hughes E, Kurian AW, et al. Comprehensive breast cancer risk assessment for CHEK2 and ATM pathogenic variant carriers incorporating a polygenic risk score and the Tyrer–Cuzick model. JCO Precis Oncol. 2021. https://doi.org/10.1200/PO.20.00484 .
doi: 10.1200/PO.20.00484
pubmed: 34322652
pmcid: 8238281
Stevanato KP, Pedroso RB, Iora P, et al. Comparative analysis between the Gail, Tyrer–Cuzick and BRCAPRO models for breast cancer screening in Brazilian population. Asian Pac J Cancer Prev. 2019;20(11):3407–13. https://doi.org/10.31557/APJCP.2019.20.11.3407 .
doi: 10.31557/APJCP.2019.20.11.3407
pubmed: 31759366
pmcid: 7063010
Brentnall AR, Cuzick J. Risk models for breast cancer and their validation. Stat Sci. 2020;35(1):14–30. https://doi.org/10.1214/19-STS729 .
doi: 10.1214/19-STS729
pubmed: 32226220
pmcid: 7100774
Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer. London: National Institute for Health and Care Excellence (NICE); November 2019.
DeCensi A, Puntoni M, Guerrieri-Gonzaga A, et al. Randomized placebo controlled trial of low-dose tamoxifen to prevent local and contralateral recurrence in breast intraepithelial neoplasia. J Clin Oncol. 2019;37(19):1629–37. https://doi.org/10.1200/JCO.18.01779 .
doi: 10.1200/JCO.18.01779
pubmed: 30973790
pmcid: 6601429
Monticciolo DL, Newell MS, Moy L, Niell B, Monsees B, Sickles EA. Breast cancer screening in women at higher-than-average risk: recommendations from the ACR. J Am Coll Radiol. 2018;15(3):408–14. https://doi.org/10.1016/j.jacr.2017.11.034 .
doi: 10.1016/j.jacr.2017.11.034
pubmed: 29371086
Mariscotti G, Belli P, Bernardi D, et al. Mammography and MRI for screening women who underwent chest radiation therapy (lymphoma survivors): recommendations for surveillance from the Italian College of Breast Radiologists by SIRM. Radiol Med. 2016;121(11):834–7. https://doi.org/10.1007/s11547-016-0667-9 .
doi: 10.1007/s11547-016-0667-9
pubmed: 27406629
Provinciali N, Suen C, Dunn BK, DeCensi A. Raloxifene hydrochloride for breast cancer risk reduction in postmenopausal women. Expert Rev Clin Pharmacol. 2016;9(10):1263–72. https://doi.org/10.1080/17512433.2016.1231575 .
doi: 10.1080/17512433.2016.1231575
pubmed: 27583816
Heemskerk-Gerritsen BAM, Jager A, Koppert LB, et al. Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2019;177(3):723–33. https://doi.org/10.1007/s10549-019-05345-2 .
doi: 10.1007/s10549-019-05345-2
pubmed: 31302855
pmcid: 6745043
Tung NM, Boughey JC, Pierce LJ, et al. Management of hereditary breast cancer: American society of clinical oncology, american society for radiation oncology, and society of surgical oncology guideline. J Clin Oncol. 2020;38(18):2080–106. https://doi.org/10.1200/JCO.20.00299 .
doi: 10.1200/JCO.20.00299
pubmed: 32243226
Manahan ER, Kuerer HM, Sebastian M, et al. Consensus guidelines on genetic testing for hereditary breast cancer from the American Society of Breast Surgeons. Ann Surg Oncol. 2019;26(10):3025–31. https://doi.org/10.1245/s10434-019-07549-8 .
doi: 10.1245/s10434-019-07549-8
pubmed: 31342359
pmcid: 6733830
Domchek SM, Friebel TM, Singer CF, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010;304(9):967–75. https://doi.org/10.1001/jama.2010.1237 .
doi: 10.1001/jama.2010.1237
pubmed: 20810374
pmcid: 2948529
Jiang X, McGuinness JE, Sin M, Silverman T, Kukafka R, Crew KD. Identifying women at high risk for breast cancer using data from the electronic health record compared with self-report. JCO Clin Cancer Inform. 2019;3:1–8. https://doi.org/10.1200/CCI.18.00072 .
doi: 10.1200/CCI.18.00072
pubmed: 31419181
Hajian-Tilaki K, Nikpour M. Accuracy of self-perceived risk perception of breast cancer development in Iranian women. BMC Womens Health. 2021;21(1):93. https://doi.org/10.1186/s12905-021-01238-z .
doi: 10.1186/s12905-021-01238-z
pubmed: 33663481
pmcid: 7934235
de Jonge ET, Vlasselaer J, Van de Putte G, Schobbens JC. The construct of breast cancer risk perception: need for a better risk communication? Facts Views Vis Obgyn. 2009;1(2):122–9.
pubmed: 25478077
pmcid: 4251271
Fehniger J, Livaudais-Toman J, Karliner L, et al. Perceived versus objective breast cancer risk in diverse women. J Womens Health (Larchmt). 2014;23(5):420–7. https://doi.org/10.1089/jwh.2013.4516 .
doi: 10.1089/jwh.2013.4516
pubmed: 24372085
Daly MB, Pal T, Berry MP, et al. Genetic/familial high-risk assessment: breast, ovarian, and pancreatic, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19(1):77–102. https://doi.org/10.6004/jnccn.2021.0001 .
doi: 10.6004/jnccn.2021.0001
pubmed: 33406487
Manahan ER, Kuerer HM, Sebastian M, et al. Consensus guidelines on genetic testing for hereditary breast cancer from the American Society of Breast Surgeons. Ann Surg Oncol. 2019;26(10):3025–31. https://doi.org/10.1245/s10434-019-07549-8 .
doi: 10.1245/s10434-019-07549-8
pubmed: 31342359
pmcid: 6733830
Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA. 2017;317(23):2402–16. https://doi.org/10.1001/jama.2017.7112 .
doi: 10.1001/jama.2017.7112
pubmed: 28632866
Corso G, Intra M, Trentin C, Veronesi P, Galimberti V. CDH1 germline mutations and hereditary lobular breast cancer. Fam Cancer. 2016;15(2):215–9. https://doi.org/10.1007/s10689-016-9869-5 .
doi: 10.1007/s10689-016-9869-5
pubmed: 26759166
Cragun D, Weidner A, Tezak A, Clouse K, Pal T. Cancer risk management among female BRCA1/2, PALB2, CHEK2, and ATM carriers. Breast Cancer Res Treat. 2020;182(2):421–8. https://doi.org/10.1007/s10549-020-05699-y .
doi: 10.1007/s10549-020-05699-y
pubmed: 32445176
Carbine NE, Lostumbo L, Wallace J, Ko H. Risk-reducing mastectomy for the prevention of primary breast cancer. Cochrane Database Syst Rev. 2018;4(4):CD002748. https://doi.org/10.1002/14651858.CD002748.pub4 .
doi: 10.1002/14651858.CD002748.pub4
pubmed: 29620792
Antoniou AC, Casadei S, Heikkinen T, et al. Breast-cancer risk in families with mutations in PALB2. N Engl J Med. 2014;371(6):497–506. https://doi.org/10.1056/NEJMoa1400382 .
doi: 10.1056/NEJMoa1400382
pubmed: 25099575
pmcid: 4157599
Roznovjak D, Petroll AE, Lakatos AEB, Narayan R, Cortina CS. Perceptions of transgender and nonbinary persons toward breast and cervical cancer development, screening, and potential impact on gender-affirming hormone therapy. JCO Oncol Pract. 2023;19(5):e794–800. https://doi.org/10.1200/OP.22.00681 .
doi: 10.1200/OP.22.00681
pubmed: 36800556
Roznovjak D, Petroll AE, Cortina CS. Breast cancer risk and screening in transgender individuals. Curr Breast Cancer Rep. 2021;13(1):56–61. https://doi.org/10.1007/s12609-020-00403-x .
doi: 10.1007/s12609-020-00403-x
Luehmann N, Ascha M, Chwa E, et al. A Single-center study of adherence to breast cancer screening mammography guidelines by transgender and non-binary patients. Ann Surg Oncol. 2022;29(3):1707–17. https://doi.org/10.1245/s10434-021-10932-z .
doi: 10.1245/s10434-021-10932-z
pubmed: 34704183
Canet ML, Harbron R, Thierry-Chef I, Cardis E. Cancer effects of low to moderate doses of ionising radiation in young people with cancer predisposing conditions: a systematic review. Cancer Epidemiol Biomarkers Prev. 2022;31:1871–89. https://doi.org/10.1158/1055-9965.EPI-22-0393 .
doi: 10.1158/1055-9965.EPI-22-0393
pubmed: 35861626
pmcid: 9530642
Brentnall AR, Cuzick J, Buist DSM, Bowles EJA. Long-term accuracy of breast cancer risk assessment combining classic risk factors and breast density. JAMA Oncol. 2018;4(9):e180174. https://doi.org/10.1001/jamaoncol.2018.0174 .
doi: 10.1001/jamaoncol.2018.0174
pubmed: 29621362
pmcid: 6143016
Rebbeck TR, Friebel T, Lynch HT, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 2004;22(6):1055–62. https://doi.org/10.1200/JCO.2004.04.188 .
doi: 10.1200/JCO.2004.04.188
pubmed: 14981104
Flowers CI, Mooney BP, Drukteinis JS. Clinical and imaging surveillance following breast cancer diagnosis. Am Soc Clin Oncol Educ Book. 2012. https://doi.org/10.14694/EdBook_AM.2012.32.220 .
doi: 10.14694/EdBook_AM.2012.32.220
pubmed: 24451710
Runowicz CD, Leach CR, Henry NL, et al. American cancer society/American society of clinical oncology breast cancer survivorship care guideline. CA Cancer J Clin. 2016;66(1):43–73. https://doi.org/10.3322/caac.21319 .
doi: 10.3322/caac.21319
pubmed: 26641959
Smith D, Sepehr S, Karakatsanis A, Strand F, Valachis A. Yield of surveillance imaging after mastectomy with or without reconstruction for patients with prior breast cancer: a systematic review and meta-analysis. JAMA Netw Open. 2022;5(12):e2244212. https://doi.org/10.1001/jamanetworkopen.2022.44212 .
doi: 10.1001/jamanetworkopen.2022.44212
pubmed: 36454573
pmcid: 9716401
Giannotti DG, Hanna SA, Cerri GG, Barbosa Bevilacqua JL. Analysis of skin flap thickness and residual breast tissue after mastectomy. Int J Radiat Oncol Biol Phys. 2018;102(1):82–91. https://doi.org/10.1016/j.ijrobp.2018.05.023 .
doi: 10.1016/j.ijrobp.2018.05.023
pubmed: 30102208
Kaidar-Person O, Boersma LJ, Poortmans P, et al. Residual glandular breast tissue after mastectomy: a systematic review. Ann Surg Oncol. 2020;27(7):2288–96. https://doi.org/10.1245/s10434-020-08516-4c .
doi: 10.1245/s10434-020-08516-4c
pubmed: 32390098
Martinez EO, Rubin M, Miller T, Cortina CS. Transgender and non-binary persons in contemporary oncology randomized clinical trials. Ann Surg Oncol. 2022;29(13):7958–60. https://doi.org/10.1245/s10434-022-12418-y .
doi: 10.1245/s10434-022-12418-y
pubmed: 35999415
East EG, Gast KM, Kuzon WM Jr, Roberts E, Zhao L, Jorns JM. Clinicopathological findings in female-to-male gender-affirming breast surgery. Histopathology. 2017;71(6):859–65. https://doi.org/10.1111/his.13299 .
doi: 10.1111/his.13299
pubmed: 28657118
Van Renterghem SMJ, Van Dorpe J, Monstrey SJ, et al. Routine histopathological examination after female-to-male gender-confirming mastectomy. Br J Surg. 2018;105(7):885–92. https://doi.org/10.1002/bjs.10794 .
doi: 10.1002/bjs.10794
pubmed: 29623678
Baker GM, Guzman-Arocho YD, Bret-Mounet VC, et al. Testosterone therapy and breast histopathological features in transgender individuals. Mod Pathol. 2021;34(1):85–94. https://doi.org/10.1038/s41379-020-00675-9 .
doi: 10.1038/s41379-020-00675-9
pubmed: 32939016
Parmeshwar N, Song S, Alcon A, Kim EA. The incidence of breast cancer after gender-affirming mastectomy in transmen. Ann Plast Surg. 2022;88(4 Suppl 4):S332–6. https://doi.org/10.1097/SAP.0000000000003083 .
doi: 10.1097/SAP.0000000000003083
pubmed: 35180758
Valero MG, Zabor EC, Park A, et al. The Tyrer–Cuzick model inaccurately predicts invasive breast cancer risk in women with LCIS. Ann Surg Oncol. 2020;27(3):736–40. https://doi.org/10.1245/s10434-019-07814-w .
doi: 10.1245/s10434-019-07814-w
pubmed: 31559544
King TA, Pilewskie M, Muhsen S, et al. Lobular carcinoma in situ: a 29-year longitudinal experience evaluating clinicopathologic features and breast cancer risk. J Clin Oncol. 2015;33(33):3945–52. https://doi.org/10.1200/JCO.2015.61.4743 .
doi: 10.1200/JCO.2015.61.4743
pubmed: 26371145
pmcid: 4934644
Klement KA, Hijjawi JB, Neuner J, Kelley K, Kong AL. Discussion of preoperative mammography in women undergoing reduction mammaplasty. Breast J. 2019;25(3):439–43. https://doi.org/10.1111/tbj.13237 .
doi: 10.1111/tbj.13237
pubmed: 30924231
Cortina CS, Siegel EL, Polovneff A, et al. Current insurance policy coverage for screening mammography in transgender and gender-diverse individuals. Ann Surg Oncol. 2023;30(12):6978–80. https://doi.org/10.1245/s10434-023-14195-8 .
doi: 10.1245/s10434-023-14195-8
pubmed: 37620531
Alcon A, Kennedy A, Wang E, et al. Quantifying the psychosocial benefits of masculinizing mastectomy in trans male patients with patient-reported outcomes: the University of California, San Francisco, Gender Quality of Life Survey. Plast Reconstr Surg. 2021;147(5):731e–40e. https://doi.org/10.1097/PRS.0000000000007883 .
doi: 10.1097/PRS.0000000000007883
pubmed: 33890884
Pusic AL, Klassen AF, Scott AM, Klok JA, Cordeiro PG, Cano SJ. Development of a new patient-reported outcome measure for breast surgery: the BREAST-Q. Plast Reconstr Surg. 2009;124(2):345–53. https://doi.org/10.1097/PRS.0b013e3181aee807 .
doi: 10.1097/PRS.0b013e3181aee807
pubmed: 19644246
Klassen AF, Kaur M, Johnson N, et al. International phase I study protocol to develop a patient-reported outcome measure for adolescents and adults receiving gender-affirming treatments (the GENDER-Q). BMJ Open. 2018;8(10):e025435. https://doi.org/10.1136/bmjopen-2018-025435 .
doi: 10.1136/bmjopen-2018-025435
pubmed: 30344182
pmcid: 6196938